ArticleCureus2026
Pediatric Parapneumonic Empyema: Trends in the Post-COVID-19 Era in Northern India.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction The coronavirus disease 2019 (COVID-19) pandemic disrupted immunization services, and regular checkups were hampered, as the entire health infrastructure was focused on the management of the COVID-19 pandemic. During the pandemic, infectious diseases decreased because of a number of factors. This study was conducted to investigate changes in the incidence of empyema cases in the post-COVID-19 era, in comparison to pre-COVID-19 times. Methods This was an ambispective observational study of all cases of thoracic empyema admitted under the Department of Pediatrics in the Government Institute of Medical Sciences, Greater Noida, Uttar Pradesh, India, over a period of one and a half years, from June 2023 to December 2024, after the COVID-19 pandemic ended. The objectives were to evaluate the clinical characteristics, outcomes, and frequency of empyema cases after the COVID-19 pandemic. Patients aged 1 month to 14 years with pneumonia and empyema were included. Demographic and clinical parameters, presence of any comorbid illnesses, nutritional status, details of investigations, and other relevant information were collected in a predesigned case record form. Results The percentage of empyema cases during the study period was 0.56%. The majority of patients were below five years of age. Pneumonia was the most common predisposing factor. The percentage of tuberculosis empyema cases was also higher than in earlier periods; culture positivity was low, and fibrinolytics were used in a higher percentage of patients. Conclusions In this region, in post-COVID-19 times, the rate of pediatric parapneumonic empyema cases has decreased. The use of intrapleural fibrinolytic therapy (IFT) has increased, and surgical intervention can often be avoided if fibrinolytic therapy is used promptly.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.